Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.
144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biotech InnovationResearchers reported that tau can trigger reverse electron transport in mitochondria, sending electrons in the opposite direction of their usual relay. Blocking that process reversed many harmful effects and improved learning and memory in flies and mice, though whether the same will hold true in people remains unclear.
Emily CarterAug 9, 2026
Biopharmaceutical IndustryWith the pharmaceutical sector witnessing heightened merger and acquisition (M&A) activity in 2026, industry analysts and investors are closely watching how juggernauts like Pfizer plc navigate a landscape defined by rising valuations, regulatory scrutiny, and strategic shifts. CEO Albert Bourla’s recent statements defending Pfizer’s $7 billion bolt-on strategy, even as peers pursue bigger deals, offer critical insight into the evolving playbook for pharma growth in a post-pandemic world.
Emily CarterAug 4, 2026
Regulatory & PolicyThe rare disease and gene therapy sector is witnessing increasing regulatory oversight as UniQure advances its Huntington’s disease gene therapy toward an FDA advisory committee review. The company’s experience reflects broader jitters in the biopharma landscape, especially after the FDA’s recent hesitation with assets from Replimune and Capricor.
Emily CarterJul 31, 2026
Biopharmaceutical IndustryPrescription drug spending has come under renewed attention as industry and regulatory changes—including updates to the No Surprises Act and surging arbitration costs—impact patients, providers, and payers. This analytical deep dive explores the key factors shaping the current drug cost debate, highlighting the pressures driving policy interventions and the ongoing challenge of balancing innovation, access, and affordability.
Emily CarterJul 27, 2026
Biotech InnovationIn a major regulatory development, Otsuka wins FDA approval for Simtriyo, the world’s first triple reuptake inhibitor for ADHD. The launch opens a new chapter in ADHD drug innovation as the company prepares for commercialization pending DEA scheduling.
Emily CarterJul 27, 2026
Biopharmaceutical IndustryA significant partnership emerges in employer-sponsored health benefits as Priority Health teams up with Color Health and Grail to deliver enhanced cancer navigation and diagnostic solutions. The collaboration is poised to offer comprehensive virtual support and advanced early detection technology to self-funded employers, reshaping the future of workplace cancer care.
Emily CarterJul 26, 2026
Biotech InnovationScribe Therapeutics has set the stage for renewed interest in gene editing companies by completing an initial public offering valued at $129 million. This long-form analysis dives deep into the context, market conditions, scientific promise, and future outlook for not just Scribe but the gene editing sector at large—spotlighting the pursuit of epigenetic silencing therapies and the evolution of CRISPR-derived medicines beyond rare diseases.
Emily CarterJul 25, 2026
Regulatory & PolicyEuropean regulatory authorities have initiated unprecedented action to ensure that the results of clinical trials are publicly accessible, meeting both legal mandates and increasing societal expectations around research transparency. This development is seen by advocacy groups as a transformative moment for the continent’s biomedical sector, signaling new accountability for industry and academia alike.
Emily CarterJul 23, 2026
Regulatory & PolicyGrowing job dissatisfaction and uncertainty over healthcare access are converging in the U.S., according to a new study and supplementary reporting. The findings underscore how the nation's healthcare system shapes labor markets, household well-being, and public health, making this a pivotal moment for policymakers and employers to reconsider entrenched benefits structures.
Emily CarterJul 22, 2026
Medical TechnologyNabla, a Paris-based AI-driven medical scribe company, has announced Brian Manning as its new CEO. The leadership change comes at a strategic moment as digital scribe vendors face mounting pressure to differentiate their technology and expand reach in the crowded clinical documentation market.
Emily CarterJul 21, 2026
AI in Drug DiscoveryBMS becomes the third major drugmaker in less than a year to announce the construction of the 'largest' NVIDIA AI supercomputer in pharma, reflecting escalating competition and unprecedented digital infrastructure investment across the industry.
Emily CarterJul 20, 2026
Biotech InnovationHarnessing advances in cell therapy, Kyverna Therapeutics is approaching an historic FDA submission for a CAR T therapy in autoimmune disease. The company's 'pipeline-in-a-product' strategy highlights both innovation and the ongoing evolution of cell therapies in treating complex immunologic disorders.
Emily CarterJul 20, 2026